Status:
COMPLETED
Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis
Lead Sponsor:
University of Michigan
Conditions:
Systemic Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
We propose to examine several angiogenic/angiostatic mediators in the skin and serum of subjects with SSc and compare it to levels found in the skin and serum of healthy subjects.
Detailed Description
Systemic sclerosis (SSc) is a connective tissue disease that is characterized by fibrosis of the skin and internal organs. One of the earliest pathologic changes in patients with SSc is damage to the ...
Eligibility Criteria
Inclusion
- Meet American College of Rheumatology criteria for systemic sclerosis
- Subjects with systemic sclerosis must have involvement proximal to the knee or elbow, excluding the face
- Persons with no chronic health conditions
Exclusion
- Persons with systemic sclerosis as a result of being exposed to chemicals or drugs that can cause a sceroderma-like illness
- Persons with autoimmune diseases other than systemic sclerosis
- Persons treated with cyclophosphamide in the last 8 weeks
- Persons with active infections, including but not limited to hepatitis C, hepatitis B, and HIV
- Persons prone to bleeding because they are treated with medications that thin the blood or have a low platelet count
Key Trial Info
Start Date :
May 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00668473
Start Date
May 1 2007
End Date
January 1 2012
Last Update
October 26 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Hospitals
Ann Arbor, Michigan, United States, 48109